Intersex Treatments

Find Intersex Treatments

Generic Name

Cypionate

Brand Names

Depo-Estradiol, Depo-Testosterone, Azmiro

FDA approval date: July 25, 1979

Classification: Androgen

Form: Injection, Kit

What is Depo-Estradiol (Cypionate)?

Testosterone Cypionate Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism - gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Safety and efficacy of Testosterone Cypionate Injection in men with “age-related hypogonadism” have not been established.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Randomized Phase II Study Comparing Sequential High Dose Testosterone and Enzalutamide to Enzalutamide Alone in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer

Who is this study for: Adult patients with metastatic castration-resistant prostate cancer

Enrollment Status: Recruiting

Publish Date: April 06, 2026

Intervention Type: Drug

Study Drugs: Testosterone cypionate, Enzalutamide, Testosterone enanthate

Study Phase: Phase 2

Summary: Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.

A Phase 2a Study of High Dose Testosterone Followed by Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer

Enrollment Status: Recruiting

Publish Date: March 17, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.5 months.

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response Via Modulation of ANdrogen Receptor (the SPIDERMAN Trial)

Enrollment Status: Recruiting

Publish Date: March 11, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: The objective of this study is to determine the safety and clinical effects of alternating pharmacologic (i.e. supraphysiologic) testosterone therapy with darolutamide in men with metastatic prostate cancer as first line hormonal therapy. Correlative studies will be conducted to assess the effect of alternating therapy on quality of life, gene expression and metabolic changes associated with alter...

View All Clinical Trials